BH3 mimetic ABT-263 enhances the anticancer effects of apigenin in tumor cells with activating EGFR mutation

BACKGROUND: Mutated epidermal growth factor receptor (EGFR) is one of the most successful targets in cancer targeted therapy. While this treatment has benefited many patients with an activating EGFR mutation (EGFRm), almost all those who initially benefited will eventually develop acquired drug resi...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhan, Yihong, Wang, Yue, Qi, Miao, Liang, Panpan, Ma, Yu, Li, Ting, Li, Hui, Dai, Congmei, An, Zhifeng, Qi, Yitao, Wu, Hongmei, Shao, Huanjie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6651933/
https://www.ncbi.nlm.nih.gov/pubmed/31367332
http://dx.doi.org/10.1186/s13578-019-0322-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6651933/
https://www.ncbi.nlm.nih.gov/pubmed/31367332
http://dx.doi.org/10.1186/s13578-019-0322-y

Ejemplares similares